- Home
- RNXT vs CLGN Comparison
RNXT vs CLGN Comparison
Compare RNXT & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- CLGN
- Stock Information
- Founded
- RNXT 2012
- CLGN 2004
- Country
- RNXT United States
- CLGN Israel
- Employees
- RNXT N/A
- CLGN N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- RNXT Health Care
- CLGN Health Care
- Exchange
- RNXT Nasdaq
- CLGN Nasdaq
- Market Cap
- RNXT 35.2M
- CLGN 33.8M
- IPO Year
- RNXT 2021
- CLGN N/A
- Fundamental
- Price
- RNXT $0.78
- CLGN $1.94
- Analyst Decision
- RNXT Strong Buy
- CLGN Strong Buy
- Analyst Count
- RNXT 2
- CLGN 2
- Target Price
- RNXT $7.50
- CLGN $11.50
- AVG Volume (30 Days)
- RNXT 371.1K
- CLGN 30.5K
- Earning Date
- RNXT 11-13-2025
- CLGN 12-01-2025
- Dividend Yield
- RNXT N/A
- CLGN N/A
- EPS Growth
- RNXT N/A
- CLGN N/A
- EPS
- RNXT N/A
- CLGN N/A
- Revenue
- RNXT $928,000.00
- CLGN $2,402,000.00
- Revenue This Year
- RNXT $2,895.35
- CLGN $1,617.28
- Revenue Next Year
- RNXT $313.04
- CLGN $83.54
- P/E Ratio
- RNXT N/A
- CLGN N/A
- Revenue Growth
- RNXT N/A
- CLGN 248.62
- 52 Week Low
- RNXT $0.70
- CLGN $1.31
- 52 Week High
- RNXT $1.69
- CLGN $4.98
- Technical
- Relative Strength Index (RSI)
- RNXT 31.87
- CLGN 38.02
- Support Level
- RNXT $0.91
- CLGN $1.85
- Resistance Level
- RNXT $1.09
- CLGN $2.27
- Average True Range (ATR)
- RNXT 0.09
- CLGN 0.11
- MACD
- RNXT -0.02
- CLGN -0.02
- Stochastic Oscillator
- RNXT 14.69
- CLGN 27.78
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.